doi: 10.1161/hs0402.105339
(Stroke. 2002;33:982.)
© 2002 American Heart Association, Inc.
Original Contributions |
Inflammation-Mediated Damage in Progressing Lacunar Infarctions
A Potential Therapeutic Target
From the Section of Neurology (M.C., J.S., A.D.) and Unit of Biostatistics (M.M.G.), Hospital Universitari Doctor Josep Trueta, Girona, Spain; Service of Neurology, Hospital Clínico Universitario (J.C., R.L.), Santiago de Compostela, Spain; and Service of Neurology, Hospital Clinic Universitari (A.C.), Barcelona, Spain.
Correspondence to Dr Antoni Dávalos, Sección de Neurología, Hospital Universitari Doctor Josep Trueta, 17007 Girona, Spain. E-mail adavalose{at}meditex.es
Background and Purpose— The mechanisms underlying neurological deterioration in patients with lacunar infarction are not completely understood. In this study, we sought to investigate the role of proinflammatory molecules in the early worsening and outcome of acute lacunar stroke.
Methods— We performed a secondary analysis of 113 consecutive patients with lacunar infarction included within the first 24 hours of the onset of symptoms in a previous study aimed at investigating clinical and biochemical factors of early neurological deterioration (END). END was defined as a fall of 
1 points in the motor items of Canadian Stroke Scale between inclusion and 48 hours. Poor outcome at 3 months was considered death or Barthel Index <85. Interleukin-6 (IL-6), tumor necrosis factor-
(TNF-), and intercellular adhesion molecule-1 (ICAM-1) were determined by enzyme-linked immunoabsorbent assay in blood samples obtained on admission.
Results— END was recorded in 27 patients (23.9%); poor outcome was noted in 26 (23%). Median (quartiles) concentrations in plasma of TNF- [16.5 pg/mL (13.7 and 21.2 pg/mL) versus 7.5 pg/mL (6.2 and 9.0 pg/mL)], IL-6 [28.8 pg/mL (22.5 and 35.7 pg/mL) versus 11.5 pg/mL (8.5 and 16.2 pg/mL)], and ICAM-1 [285 pg/mL (219 and 315 pg/mL) versus 158 pg/mL (137 and 187 pg/mL)] were significantly higher in patients who had END than in those with nonprogressing strokes (P< 0.001). Significant differences were also observed between patients with poor and good outcome at 3 months. Logistic regression analysis after adjustment for potential confounders showed that TNF- >14 pg/mL and ICAM-1 >208 pg/mL were independently associated with both END (OR, 511; 95% CI, 17 to 4937; P<0.001; and OR, 315; 95% CI, 17 to 5748; P< 0.001, respectively) and poor outcome at 3 months (OR, 3.0; 95% CI, 1.0 to 8.5; P=0.042; and OR, 4.2; 95% CI, 1.3 to 13.6; P<0.015, respectively).
Conclusions— High concentrations of inflammatory markers in blood are associated with END and poor functional outcome in lacunar infarctions. These findings suggest that inflammation contributes to brain injury in lacunar stroke.
Key Words: cytokines • inflammation • lacunar infarction • stroke outcome
This article has been cited by other articles:
 |
|
 |
|
  B. Guldiken, S. Guldiken, B. Turgut, N. Turgut, M. Demir, Y. Celik, E. Arikan, and A. Tugrul The Roles of Oxidized Low-Density Lipoprotein and Interleukin-6 Levels in Acute Atherothrombotic and Lacunar Ischemic Stroke Angiology, May 1, 2008; 59(2): 224 - 229. [Abstract] [PDF]
|
|
|
|
 |
|
 A. R. Tso, J. G. Merino, and S. Warach Interleukin-6 174G/C Polymorphism and Ischemic Stroke: A Systematic Review Stroke, November 1, 2007; 38(11): 3070 - 3075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. Chen, P. Y. Wang, W. H. Sheu, Y. T. Chen, Y. P. Ho, H. H. Hu, and H. Y. Hsu Changes of brachial flow-mediated vasodilation in different ischemic stroke subtypes. Neurology, September 26, 2006; 67(6): 1056 - 1058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tedgui and Z. Mallat Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways Physiol Rev, April 1, 2006; 86(2): 515 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Y. Cheranov and J. H. Jaggar TNF-{alpha} dilates cerebral arteries via NAD(P)H oxidase-dependent Ca2+ spark activation Am J Physiol Cell Physiol, April 1, 2006; 290(4): C964 - C971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tedgui The role of inflammation in atherothrombosis: implications for clinical practice Vascular Medicine, February 1, 2005; 10(1): 45 - 53. [Abstract] [PDF]
|
|
|
|
|
|
H. J. Audebert, M. M. Rott, T. Eck, and R. L. Haberl Systemic Inflammatory Response Depends on Initial Stroke Severity but Is Attenuated by Successful Thrombolysis Stroke, September 1, 2004; 35(9): 2128 - 2133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Barber, P. Langhorne, A. Rumley, G. D.O. Lowe, and D. J. Stott Hemostatic Function and Progressing Ischemic Stroke: D-dimer Predicts Early Clinical Progression Stroke, June 1, 2004; 35(6): 1421 - 1425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Pola, A. Flex, E. Gaetani, R. Flore, M. Serricchio, and P. Pola Synergistic Effect of -174 G/C Polymorphism of the Interleukin-6 Gene Promoter and 469 E/K Polymorphism of the Intercellular Adhesion Molecule-1 Gene in Italian Patients With History of Ischemic Stroke Stroke, April 1, 2003; 34(4): 881 - 885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Vila, J. Castillo, A. Davalos, A. Esteve, A. M. Planas, and A. Chamorro Levels of Anti-Inflammatory Cytokines and Neurological Worsening in Acute Ischemic Stroke Stroke, March 1, 2003; 34(3): 671 - 675. [Abstract] [Full Text] [PDF]
|
|